{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CASRegistryName","name":"1420477-60-6"},{"type":"CodeName","name":"ACP 196"},{"type":"CodeName","name":"ACP-196"},{"type":"CodeName","name":"ACP196"},{"type":"ChemicalStructureName","name":"benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-"},{"type":"Synonym","name":"Bruton tyrosine kinase inhibitor ACP-196"}],"definition":{"html":"An orally available inhibitor of Bruton tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","text":"An orally available inhibitor of Bruton tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival."},"drugInfoSummaryLink":null,"nciConceptId":"C113442","nciConceptName":"Acalabrutinib","termId":818156,"name":"acalabrutinib","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"acalabrutinib"},{"aliases":[{"type":"CodeName","name":"acalabrutinib maleate anhydrous"},{"type":"USBrandName","name":"Calquence"},{"type":"CASRegistryName","name":"2641500-53-8"}],"definition":{"html":"The maleate monohydrate form of acalabrutinib, an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","text":"The maleate monohydrate form of acalabrutinib, an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/acalabrutinib","text":"Acalabrutinib Maleate Monohydrate"},"nciConceptId":"C189925","nciConceptName":"Acalabrutinib Maleate Monohydrate","termId":756623,"name":"acalabrutinib maleate monohydrate","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"acalabrutinib-maleate-monohydrate"}],"links":null}